Weerayuth carlo weerayuth Saelim

Dr. Weerayuth carlo weerayuth Saelim

Department of Pharmaceutical care, Faculty of Pharmacy, Silpakorn University, Thailand, Nakhon Pathom, Thailand
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
WSWeerayuth carlo weerayuth Saelim
Weerayuth carlo weerayuth Saelim
DCDhitiwat Changpradub
Dhitiwat Changpradub
STSudaluck Thunyaharn
Sudaluck Thunyaharn
PJPiraporn Juntanawiwat
Piraporn Juntanawiwat
PNParnrada Nulsopapon
Parnrada Nulsopapon
WSWichai Santimaleeworagun
Wichai Santimaleeworagun
Saelim W, et al. Infect Chemother. 2021 Mar;53:e16. https://doi.org/10.3947/ic.2021.0007

18 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Sutee LimcharoenSutee Limcharoen
Sutee Limcharoen
MPManat Pongchaidecha
Manat Pongchaidecha
PPPiyarat Pimsi
Piyarat Pimsi
SLSarawuth Limprasert
Sarawuth Limprasert
JSJuthathip Suphanklang
Juthathip Suphanklang
PBPornwalai Boonmuang
Pornwalai Boonmuang
Apixaban can significantly prevent stroke events in patients with non-valvular atrial fibrillation (NVAF), as can be observed from the large, randomized, controlled trial conducted in the present study. However, the real-world evidence of bleeding events related to the apixaban plasma levels in Asian populations is limited. This study aimed to investigate the apixaban plasma levels and clinical outcomes among NVAF patients receiving apixaban, including determining the risk factors associated with bleeding during routine care. Seventy-one patients were included in the study. The median values were 112.79 (5–95th percentiles: 68.69–207.8) μg/L and 185.62 (5–95th percentiles: 124.06–384.34) μg/L for the apixaban trough (Ctrough) and apixaban peak plasma levels (Cpeak), respectively. Stroke and bleeding were found in 8 (11.27%) and 14 patients (19.72%), respectively. There was no statistical significance for Ctrough and Cpeak in the stroke and non-stroke groups, respectively. The median of Ctrough (139.15 μg/L) in patients with bleeding was higher than that in the non-bleeding group (108.14 μg/L), but there was no statistical significance. However, multivariate analyses showed that bleeding history (odds ratio (OR): 17.62; 95% confidence interval (CI): 3.54–176.64; and p-value = 0.002) and Ctrough (OR: 1.01; 95%: CI 1.00–1.03; and p-value = 0.038) were related to bleeding events. Almost all of the patients presented apixaban plasma levels within the expected range. Interestingly, bleeding events were associated with the troughs of the apixaban plasma levels and bleeding history.

1 October 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JWJutharat Watcharasuwanseree
Jutharat Watcharasuwanseree
WCWorawong Chueansuwan
Worawong Chueansuwan
NSNuntra Suwantarat
Nuntra Suwantarat
WSWichai Santimaleeworagun
Wichai Santimaleeworagun
PJPiraporn Juntanawiwat
Piraporn Juntanawiwat
WSWeerayuth carlo weerayuth Saelim
Weerayuth carlo weerayuth Saelim
Purpose: This study aimed to determine the optimal micafungin dosage for treating candidemia in critically ill adult patients using Monte Carlo simulation. Patients and Methods: Clinical Candida isolates were obtained from blood cultures collected between September 2023 and December 2024 at Phramongkutklao Hospital, Thammasat University Hospital, and Udonthani Hospital. Susceptibility testing was performed using the Sensititre® YeastOne® system, applying a broth microdilution method in 96-well plates to determine minimum inhibitory concentrations (MICs). Monte Carlo simulations were conducted to identify optimal micafungin dosing regimens, using cumulative fraction of response (CFR) and probability of target attainment (PTA) as key parameters. Results: In total, 128 clinical Candida isolates were identified. Candida tropicalis was the most frequently isolated species (32%), followed by C. albicans (22.7%), C. parapsilosis (16.4%), C. glabrata (Nakaseomyces glabrata) (12.5%), and C. auris (Candidozyma auris) (9.4%). The micafungin MIC ranges were as follows: C. tropicalis, 0.015– 0.25 μg/mL; C. albicans, 0.008– 0.015 μg/mL; C. parapsilosis, 0.5– 2 μg/mL; C. glabrata, 0.015–> 8 μg/mL; and C. auris, 0.12– 0.25 μg/mL. Pan-echinocandin-resistant C. glabrata was also detected. A standard micafungin dose (100 mg/day) may be effective for C. tropicalis infections when MIC is ≤ 0.015 μg/mL. In patients with Sequential Organ Failure Assessment scores > 10 and alanine aminotransferase > 120 U/L, the standard micafungin dose adequate CFR for empirical therapy and PTA for documented treatment at MICs up to 0.03 μg/mL, with the target threshold set at ≥ 90%. However, in the absence of MIC data and with increasing MIC trends, a higher empirical dose (up to 400 mg/day) may be warranted. Conclusion: Non-albicans Candida bloodstream infections are increasing, along with higher MIC trends, signaling emerging resistance. Standard dosing may be insufficient in critically ill patients. Empirical high-dose micafungin could improve treatment efficacy.

14 November 2024 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
SSSujareenoot Suya
Sujareenoot Suya
Worapong NasomsongWorapong Nasomsong
Worapong Nasomsong
WSWichai Santimaleeworagun
Wichai Santimaleeworagun
PJPiraporn Juntanawiwat
Piraporn Juntanawiwat
TCTassananwan Chatreewonanakul
Tassananwan Chatreewonanakul
WSWeerayuth carlo weerayuth Saelim
Weerayuth carlo weerayuth Saelim
Objective: We aimed to use Monte Carlo simulation, based on pharmacokinetic/pharmacodynamic targets, to investigate and determine the optimal dosage of the available combination therapies for carbapenem-resistant Klebsiella pneumoniae (CRKP) in critically ill patients. Methods: We collected CRKP clinical isolates from Phramongkutklao Hospital between October 2020 and June 2022. A molecular study of resistant genes was performed using polymerase chain reaction. Broth microdilution checkerboards were used to evaluate the mono- and synergistic antibiotic activities. Monte Carlo simulation was used to determine the optimal antibiotic regimens, based on the probability of target attainment (PTA) and cumulative fraction of response. Results: The 54 CRKP isolates were resistant to tigecycline (100%), colistin (75.9%), amikacin (70.4%), and gentamicin (63.0%). The most common carbapenemase genotype was bla(oxacillinases (OXA)-48-like) (42.6%), followed by bla(New Delhi metallo beta-lactamase (NDM)) (29.6%) and coexistence of bla(OXA-48-like) and bla(NDM) (22.2%). Based on the PTA, synergistic and additive activities against CRKP isolates were observed with appropriate dosages of tigecycline-colistin (67.9%), tigecycline-gentamicin (62.2%), and tigecycline-amikacin (51.4%). Conclusions: Tigecycline-colistin was the best available combination therapy for critically ill patients with CRKP, especially NDM. When used in combination with tigecycline, a colistin creatinine clearance of <90 mL/min can raise the cumulative fraction of response target and less nephrotoxicity. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

22 July 2021 in Science, Engineering and Health Studies
Verified
Journal Article
Open access
PDF file
WSWichai Santimaleeworagun
Wichai Santimaleeworagun
PWPetch Wacharasint
Petch Wacharasint
WSWeerayuth carlo weerayuth Saelim
Weerayuth carlo weerayuth Saelim
JSJuthathip Suphanklang
Juthathip Suphanklang
KDKawin Duangmee
Kawin Duangmee
TKThanathorn Kulkiatprasert
Thanathorn Kulkiatprasert
This study aimed to determine the prevalence and antimicrobial susceptibility of causative pathogens associated with 30-day mortality among intensive care unit (ICU) patients with bloodstream infections as well as to analyze clinical outcomes and risk factors. This retrospective study was conducted at Phramongkutklao Hospital, Thailand, between October 2017 and December 2018. The study included 142 patients with bloodstream infections caused by 193 isolated pathogens. Of the 142 patients, the clinical cure and death rates were reported to be 40.1% and 62.0%, respectively. Of the 193 isolated bacterial strains, 83.4% were Gram-negative: predominately Klebsiella pneumoniae, followed by Acinetobacter baumannii, and then Pseudomonas aeruginosa isolates. Gram-positive bacteria accounted for 16.6% of the total isolated bacterial strains: Staphylococcus aureus was the leading isolate, followed by coagulase-negative staphylococci and then Enterococcus faecalis. Most of the A. baumannii isolates (97.0%) were resistant to meropenem, but 57.7% of P. aeruginosa and 40.0% of K. pneumoniae were susceptible to meropenem. Through multivariate analysis, it was found that the significant factors for 30-day mortality were male gender, catheter-related bloodstream infection, and carbapenem-resistant Gram-negative infection. Due to the high 30-day mortality rate of almost two-thirds of the study groups, healthcare professionals are challenged to select an optimized treatment regimen for ICU patients with carbapenem-resistant gram-negative infection.

13 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
KTKaratpetch Tongkate
Karatpetch Tongkate
TCThoranis Chantrarat
Thoranis Chantrarat
PBPornwalai Boonmuang
Pornwalai Boonmuang
WSWeerayuth carlo weerayuth Saelim
Weerayuth carlo weerayuth Saelim
NRNarisa Ruenroengbun
Narisa Ruenroengbun
JKJunporn Kongwatcharapong
Junporn Kongwatcharapong
Background and Objectives: While non-vitamin K antagonist oral anticoagulants (NOACs) show better renal preservation than warfarin in nonvalvular atrial fibrillation (NVAF) patients, real-world evidence within Asian populations remains limited. This study compared the renal outcomes between NOACs and warfarin in Thai patients with NVAF. Materials and Methods: A retrospective cohort study was conducted among NVAF patients who received either NOACs or warfarin from two university hospitals in Thailand from January 2015 to December 2019. The primary outcome was a ≥30% decline in the estimated glomerular filtration rate (eGFR) with a doubling of the serum creatinine (SCr), while acute kidney injury (AKI) and incidence rate of stroke and systemic embolism event (SEE) were secondary outcomes. All outcomes of each NOAC versus the warfarin group were analyzed using Cox proportional hazards regression. Results: A total of 1456 patients were enrolled. During a follow-up period of 24 months, NOACs were associated with a lower risk of a ≥30% decline in the eGFR than warfarin after inverse probability of treatment weighting (IPTW) and multivariable adjustment (adjusted hazard ratio (aHR) of 0.67, 95% confidence interval [CI] 0.45–1.00, p = 0.050). No significant differences were observed between NOACs and warfarin regarding the doubling of SCr (aHR 0.64, 95% CI 0.24–1.72, p = 0.373) or AKI (aHR 0.69, 95% CI 0.41–1.17, p = 0.169), although a trend toward a lower risk was noted in the NOAC group. Similarly, a trend toward a lower risk of the incidence rate of ischemic stroke and SEE were observed in the NOAC group (aHR 0.49, 95% CI 0.22–1.10, p = 0.084). Conclusions: In real-world data, NOACs may be associated with a lower eGFR decline and lower doubling of SCr and AKI than warfarin. Additionally, NOACs may reduce the risk of ischemic stroke and SEE, supporting their potential benefit over warfarin in both renal and thromboembolic outcomes.